Lead Gilead researcher highlights need for inclusive clinical trials for HIV
A lead researcher from Gilead’s flagship human immunodeficiency virus (HIV) PURPOSE programme has highlighted the importance of sponsors better considering trial …
Post
-
-
Aulos Bioscience doses first patient in avelumab lung cancer trial
US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, …
-
Anocca submits application to EMA for pancreatic cancer trial
Anocca has submitted its first clinical trial application (CTA) to the European Medicines Agency (EMA) for conducting the Phase I/II …
-
Real-world evidence trials set to increase for 2024
According to the FDA, real-world evidence (RWE) is clinical evidence regarding the usage, potential benefits, or risks of a medical …
-
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has …
-
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
New Jersey-based biopharma, PTC Therapeutics said its Phase II trial of utreloxastat for patients with amyotrophic lateral sclerosis (ALS) has …
-
Lexicon completes subject enrolment for DPNP trial of LX9211
Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre, Phase IIb PROGRESS trial of the new adaptor-associated kinase …
-
S.BIOMEDICS reports positive data from Parkinson’s trial of TED-A9 cell therapy
S.BIOMEDICS has reported encouraging one-year post-transplant outcomes from a Phase I/IIa study of its cell therapy, TED-A9, for treating Parkinson's …
-
Amgen share price plummets despite Phase II weight loss success
Amgen's share price has dropped despite announcing positive data from its Phase II MariTide (maridebart cafraglutide, formerly AMG 133) study, …
-
Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments
Opioid use disorder (OUD) is a chronic neurological disorder characterised by the compulsive, repeated use of opioid drugs, leading to …
-
Axsome Therapeutics eyes approval after Phase III narcolepsy win
Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), …
-
Neuralink to launch feasibility trial with implant coupled to robotic arm
US-based Neuralink has received approval to launch a new feasibility trial studying its brain implant linked with an assistive robotic …
-
Alector stock drops after Alzheimer’s drug fails in Phase II trial
Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to …
-
Roche’s tiragolumab flops in another Phase III lung cancer trial
Roche's struggles with finding a foothold for its immune checkpoint inhibitor tiragolumab the cancer treatment space have been reinforced with …
-
Slope and LabConnect launch bidirectional API integration for clinical trial companies
Slope and LabConnect have launched a bidirectional application programming interface (API) integration for the clinical trial industry. The combination of Slope's …
